Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 4, 2016, Pages 421-428

  Muralidhar, Vinayak ^a   Catalano, Paul J ^a   Reznor, Gally ^b   Mahal, Brandon A ^c   Choueiri, Toni K ^c   Sweeney, Christopher J ^c   Martin, Neil E ^c   Beard, Clair J ^c   Chen, Yu Wei ^c   Nezolosky, Michelle D ^c   Hoffman, Karen E ^d   Feng, Felix Y ^e   Trinh, Quoc Dien ^c   Nguyen, Paul L ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Surgery and Public Health   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PROSTATE CANCER; CANCER GRADING; CANCER REGISTRY; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84964325985     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0048     Document Type: Article

References (29)

1. Mohler JL, Armstrong AJ, Bahnson RR, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Verison 2.2016. Accessed March 9, 2016. To view the most recent version of these guidelines, visit NCCN.org.
2. Bolla M, De Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-2527.
3. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 2003;21:3972-3978.
4. Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16:320-327.
5. Muralidhar V, Regan MM, Werner L, et al. Duration of androgen deprivation therapy for high-risk prostate cancer: application of randomized trial data in a tertiary referral cancer center [published online ahead of print December 17, 2015]. Clin Genitourin Cancer, doi:10.1016/j.clgc.2015.12.008.
6. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825-836.
7. Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009;302:866-873.
8. Ziehr DR, Chen MH, Zhang D, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int 2015;116:358-365.
9. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359-2366.
10. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-295.
11. Greene DE, Mayadev JS, Valicenti RK. Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol 2012;4:113-124.
12. Overview of the SEER Program. National Cancer Institute; Surveillance, Epidemiology, and End Results Program Web site. Available at: http://seer. cancer.gov/about/overview.html. Accessed September 3, 2015.
13. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl): IV-3-18.
14. Shahinian VB, Kuo Y F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164.
15. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456.
16. Schmid M, Hanske J, Ravi P, et al. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer [published online ahead of print January 13, 2016]. Int J Urol, doi:10.1111/iju.13043.
17. Schmid M, Sammon JD, Reznor G, et al. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events [published online ahead of print June 13, 2015]. BJU Int, doi:10.1111/bju.
18. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267.
19. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Oncol 2013;64:895-902.
20. Muralidhar V, Chen MH, Reznor G, et al. Definition and validation of "favorable high-risk prostate cancer": implications for personalizing treatment of radiation-managed patients. Int J Radiat Oncol Biol Phys 2015;93:828-835.
21. PSA Values and SEER Data. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Available at: http://seer.cancer.gov/data/psa-values.html. Accessed September 3, 2015.
22. Furlow B. US National Cancer Institute investigates PSA coding errors. Lancet Oncol 2015;16:614.
23. Schymura MJ, Sun L, Percy-Laurry A. Prostate cancer collaborative stage data items-their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. Cancer 2014;120(Suppl 23):3758-3770.
24. Fine J P, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
25. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008;54:816-823.
26. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452-3458.
27. Ziehr DR, Mahal BA, Aizer AA, et al. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol 2015;33:18 e7-3.
28. Mahal BA, Aizer AA, Ziehr DR, et al. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 2014;84:386-392.
29. Mahal BA, Ziehr DR, Aizer AA, et al. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol 2014;32:1285-1291.